Vaxart (NASDAQ:VXRT) Full Year 2022 Results
Key Financial Results
- Net loss: US$107.8m (loss widened by 53% from FY 2021).
- US$0.84 loss per share (further deteriorated from US$0.58 loss in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Vaxart Revenues Disappoint
Revenue missed analyst estimates by 45%. Earnings per share (EPS) was mostly in line with analyst estimates.
Looking ahead, revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are up 3.7% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 5 warning signs for Vaxart (2 can't be ignored!) that you need to be mindful of.
If you're looking to trade Vaxart, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentNew: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:VXRT
Vaxart
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States.
Excellent balance sheet and good value.
Market Insights
Community Narratives
